Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 27;6(5):e13614. doi: 10.14814/phy2.13614

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Astra Zeneca. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Time profiles of predicted and observed concentration of UA in serum and cumulative amount excreted in urine for daily doses of febuxostat and lesinurad in Study 105 (90 serum samples and 54 urine samples). Left column: predose. Middle column: profiles after 7 days of febuxostat 40 mg once a day. Right column: profiles after 7 days of febuxostat 40 mg and lesinurad 400 mg once a day. Panels across columns show data for the same group of patients switching treatments every 7 days. Top row: predicted production rate of UA. Second row: predicted fractional excretion coefficient of UA in urine. Third row: concentration of UA in serum. Fourth row: cumulative amount of UA in urine (amount was reset to 0 at the start of sampling on day 7 and 14). Horizontal axis shows time after drug dose. Symbols: individual observations. Lines: model predictions. UA, uric acid. LSN, lesinurad. FBX, febuxostat.